Uniphar

H1 results support the outlook for a return to double-digit EPS growth this year

  • Sectors : Pharma and healthcare
  • Companies : Uniphar

Ratings and price correct at time of issue.

  • Uniphar

    Closing Price: 265c

  • RATING 27/08/19

  • PREVIOUS RATING N/A

Person's Name

Colin Grant

Analyst

DAVY VIEW

Uniphar’s H1 2024 results reflect strong top line and gross profit growth. All divisions are expected to achieve their growth targets this year. Ongoing investments support the medium-term ambition of €200m in EBITDA. We are leaving our forecasts unchanged and expect a resumption of double-digit EPS growth in 2024.

View full article

Download full report with analyst certification and important disclosures

Sep 3 2024, 07:10 IST/BST

Download